AstraZeneca Restarts MEK Inhibitor In Singapore Research Pact
This article was originally published in PharmAsia News
Executive Summary
With two compounds already identified for screening - including one that fizzled in Phase II for melanoma - AstraZeneca kicked off a partnership with a pair of Singapore institutions to come up with drugs for liver cancer, a disease especially prevalent in East Asia, which accounts for 75 percent of the world's patients